About This Report

Novel Vaccine Delivery System Market, by Route of Administration (Intramuscular, Intradermal, Subcutaneous, and Others), By Devices (Syringes, Needle-free injection System, and Others), and by Region (North America, South America, Europe, Asia Pacific, The Middle East, and Africa) - Size, Share, COVID Impact Analysis, Growth, Outlook, and Opportunity Analysis, 2020 - 2028

Vaccines called injections or immunisations cause the body to produce antibodies or immunity against a disease. People of all ages are generally given vaccinations, which boost their immune systems over their lifetime and provide protection against a variety of infectious diseases. The term "novel vaccine delivery system" describes the incorporation of modern technologies and creative delivery strategies for vaccinating people. These administration methods aim to increase the vaccinations' efficacy, safety, and patient compliance.

Subcutaneous injection, oral delivery, and intramuscular injection are examples of common vaccination administration techniques. Alternative vaccine administration techniques, such as transdermal, intranasal, and mucosal administration, are provided through creative vaccine delivery systems. These innovative delivery methods can boost vaccination immune responses, decrease the chance of negative side effects, and increase vaccine uptake.

In 2020, the Novel Vaccine Delivery System market was valued at US$ YY million, and it is anticipated to be around US$ YY million by 2027. Over the forecast period, the market is expected to grow at a CAGR of YY%.

Increasing prevalence of infectious diseases, and the Government initiatives to promote vaccination programs are the main drivers, but the Shortage of trained healthcare professionals is a restraint

Innovative vaccine delivery technologies are in high demand due to the rising prevalence of infectious illnesses. For instance, the World Health Organisation estimates that infectious diseases cause 13 million fatalities per year. The COVID-19 pandemic has underlined the value of immunisation even more and raised the necessity for innovative vaccine delivery technologies. To stop the spread of infectious illnesses, governments all over the world have been actively supporting vaccination programmes. For instance, to ensure that all Americans have access to COVID-19 immunisations, the US government, for instance, has started the COVID-19 Vaccination Programme. Similar to this, the Indian government has started the Universal Immunisation Programme to give all children in the nation free vaccinations.

However, a significant problem that may hinder the widespread use of inventive immunisation delivery methods is a shortage of skilled medical personnel. Without the proper training, medical personnel might not be able to use these technologies safely and effectively, which might lead to inadequate patient results and reduced confidence in the technology. For instance, as per the WHO, there is a worldwide lack of health professionals, with an estimated 18 million people required globally. The shortage of physicians has a particularly negative impact on low- and middle-income countries, which usually have insufficient resources for educating and keeping healthcare professionals.

Syringes segment is expected to account for significant market share by Devices segment

The global Novel Vaccine Delivery System market is mainly classified based on Route of Administration, and Devices. Route of Administration is divided into intramuscular, intradermal, subcutaneous, and others. By Devices segment, the market is classified into syringes, needle-free injection system, and others. Syringes is further classified into smart syringes, and conventional syringes. Needle-free injection system is again categorized into spring-based injector systems, gas propelled/air forced injector systems, and others.

By Devices segment, syringes segment is expected to grab the first position worldwide. Syringes are frequently used for injecting vaccines, and developments in syringe technology have produced safety syringes, auto-disable syringes, and prefilled syringes, all of which have raised consumer demand for them. Syringes are also anticipated to maintain their market dominance due to their low cost and simplicity of use, particularly in developing nations where healthcare infrastructure is still being developed.

Syringe technology improvements have raised consumer demand for auto-disable syringes. The automated self-disabling feature on these syringes is intended to stop the spread of illnesses and the reusing of contaminated needles after a single usage. In underdeveloped nations where the risk of needle reuse and the transmission of bloodborne infections like HIV and Hepatitis B is high due to a lack of proper healthcare infrastructure. Auto-disable syringes have been frequently utilised in mass vaccination campaigns. For instance, since 2003, the World Health Organisation (WHO) has advised using auto-disable syringes in immunisation campaigns. As a result, many nations have embraced this technology to enhance their immunisation programmes.

Interesting Facts of Novel Vaccine Delivery System Market

• The most popular way of giving vaccines is intramuscularly, which accounts for the biggest market share in the Route of Administration sector.
• Companies are investing heavily in R&D activities and collaborations to develop new and innovative vaccine delivery systems.
• The COVID-19 pandemic has increased the need for novel vaccine delivery technologies, particularly those that allow the quick administration of vaccines to a large number of people.
• Novel vaccine delivery system markets in North America and Europe are established and developed, with considerable expenditures made in healthcare infrastructure, R&D, and cutting-edge technology.

Asia Pacific will account for the largest share of the Novel Vaccine Delivery System industry

The market for Novel Vaccine Delivery System will continue to develop at a rapid pace during the forecast period in the Asia-Pacific region. The region has a significant population base and a number of economies that are developing quickly. There is an increasing need for novel vaccine delivery technologies that may boost the efficiency and safety of vaccinations as the region's healthcare infrastructure develops. Additionally, the region's expanding vaccination programmes, rising healthcare expenses, and increasing prevalence of infectious diseases are driving demand for Novel Vaccine Delivery System. Due to the increased need for vaccines caused by the COVID-19 pandemic, more focus is being given to the creation of novel vaccine delivery methods.

In the Asia-Pacific region, led by countries like China, India, and Japan, the market for novel vaccine delivery systems will likely grow quickly. The infrastructure of the healthcare system as well as R&D activities are receiving a lot of funding from these countries, which have substantial populations. Government initiatives to promote vaccination programmes and increase vaccine accessibility are also projected to assist market growth in the region. For instance, The National Medical Products Administration (NMPA) of China granted approval to CanSino Biologics Inc.'s novel Ebola vaccine delivery technology in 2019. The vaccine uses a viral vector delivery system to get the genetic information of the vaccine into cells and trigger an immune response.

Global Novel Vaccine Delivery System Market key Players:

Some of the major competitors in the global Novel Vaccine Delivery System market include Agrolabo S.p.A, Bayer AG, Boehringer Ingelheim GmbH, Ceva Santé Animale, Dechra Pharmaceuticals, Elanco Animal Health Incorporated, IDEXX Laboratories, Inc., Merck & Co., Inc., Merial, Vetoquinol S.A., Virbac, Inc., and Zoetis Inc.
The Novel Vaccine Delivery System industry is extremely competitive with aggressive market strategies of global and regional companies looking to strengthen market position through new product launches, collaborations, and facility expansions. The following are some recent market developments:

• Pfizer and BioNTech announced jointly that a COVID-19 vaccine research utilising a cutting-edge intranasal delivery technology will start in March 2022. The vaccine, which takes use of BioNTech's mRNA technology, will be administered by nasal spray.
• In February 2022, Vaxart, a biotechnology firm in clinical development, announced that the Phase 1 evaluation of its oral COVID-19 vaccine had been successfully completed. The oral tablet delivery strategy for the vaccination can improve patient compliance and reduce the risk of injury from puncture wounds.
• The Indian vaccine manufacturer Bharat Biotech announced in November 2021 that a novel nasal immunisation for COVID-19 would be made available. The vaccine uses a recombinant protein antigen and is administered as a nasal spray.
• Merck and IAVI announced that they would be working together to develop a brand-new vaccine candidate using recombinant vesicular stomatitis virus delivery technology.
• GlaxoSmithKline stated in 2021 that its vaccine production facilities in Europe, the US, and Asia will be expanding in order to fulfil the rising demand for cutting-edge vaccine delivery technologies.

Frequently asked questions about global Novel Vaccine Delivery System market

Q: What is the current size of the global Novel Vaccine Delivery System market?
Ans: The Novel Vaccine Delivery System market was valued at YY million US$ in 2020 and is projected to reach YY million US$ by 2027, at a CAGR of YY% during the forecast period.

Q: What are the major opportunities in Novel Vaccine Delivery System industry?
Ans: Technological advancements, increasing prevalence of infectious diseases, and increasing government initiatives are the major opportunities of the market.

Q: What is major growth driving factor for Novel Vaccine Delivery System industry?
Ans: The worldwide demand for efficient vaccination programmes and the rising frequency of infectious illnesses are the primary growth drivers for the novel vaccine delivery system market.

Q: Which region is expected to have the largest share of the Novel Vaccine Delivery System market?
Ans: The Asia Pacific region is anticipated to grow at the greatest CAGR throughout the projection period due to an expanding patient base, rising government initiatives for immunisation programmes, and an increase in the number of cases of infectious diseases.

Q: Which Route of Administration segment will dominate the Novel Vaccine Delivery System market?
Ans: The intramuscular market category is anticipated to maintain its dominance. The introduction of intramuscular vaccination delivery systems, which move drugs deeper into muscle fibres and enable fast absorption, is one of the reasons supporting the growth of this market.